ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for which patients chronic drug treatment could potentially be ...

荷兰的研究人员近日发现，BCR::ABL1数字PCR的临床应用能够可靠定量慢性髓系白血病（CML）的深层分子学缓解，这将有助于判断哪些患者有资格停止慢性药物治疗。 荷兰的研究人员近日发现，BCR::ABL1数字PCR的临床应用能够可靠定量慢性髓系白血病（CML）的深层分子 ...

ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to ...

AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on ...

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

总之，普纳替尼的临床应用是肿瘤治疗史上“向死而生”的典范。其以突破性疗效拯救无数濒危患者的同时，也迫使医学界重新审视“风险-获益”的伦理边界。未来，随着分子分型的精细化与毒性管理手段的革新，普纳替尼或将褪去“最后选择”的悲情色彩，进化为兼顾安全与疗效的治愈利器。在这条充满挑战的征途上，科学与人文的交织，终将照亮白血病治疗的终极愿景。 返回搜狐，查看更多 ...

引言：医学的重生从“绝境”反转到“希望”，普纳替尼（Ponatinib）的出现是一场颠覆传统的医学奇迹。在慢性粒细胞白血病（CML）和费城染色体阳性急性淋巴细胞白血病（Ph+ALL）的治疗中，BCR-ABLT315I突变曾如同高不可攀的壁垒，使得常规酪氨酸激酶抑制剂（TKI ...

白血病是一种严重威胁人类健康的血液系统恶性肿瘤，其中急性淋巴细胞白血病（ALL）在儿童和成人中都不少见。KMT2A 重排（KMT2A-R）的 ALL 更是一种高危疾病，约 75% 的 12 个月以下婴儿 ALL 病例、1 - 2% 的大龄儿童 ALL 病例以及 10% 的成人 ALL 病例存在 KMT2A 重排 。这类患者常常对化疗耐药，临床预后很差，儿童的生存率不到 ...

The American Heart Association and The Giants Foundation, the nonprofit organization of the New York Giants, gathered representatives from 12 local schools for cardiopulmonary resuscitation (CPR ...

ROCKVILLE, Md. and SUZHOU, China, March 27, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred ...

Mar. 31, 2025 — AI mental health apps may offer a cheap and accessible way to fill the gaps in the overstretched U.S. mental health care system, but ethics experts warn that we need to be ...